The Centers for Disease Control and Prevention has awarded ICF with a $31 million recompete contract to provide development, operations and maintenance support to its syndromic surveillance platform, BioSense.
The contract has a term of four years, including a 1-year base and three 1-year options.
“ICF has supported BioSense since 2014, playing an integral role in the nation’s most critical public health threat responses, including the Zika and Ebola outbreaks, the opioid epidemic and analyzing the health impacts of heat waves and other natural events,” said Mark Lee, ICF executive vice president and public sector lead.
BioSense makes it easier for local, state and national health officials to monitor and respond to health effects of exposure to disease, addiction and hazardous conditions. It has been at the forefront of the nationwide response to COVID-19, as it continuously monitors outbreak patterns and trends, and alerts health officials of “hot spots.”
ICF will work with CDC’s Division of Health Informatics and Surveillance and its partners to improve syndromic surveillance efficacy and coverage, national platform sustainability, partner and community outreach and analytic capabilities.
“We have built strong, trusted partnerships with the syndromic surveillance community and public health partners and bring the technical, analytical and public health expertise needed to continue to modernize and optimize this crucial national resource,” Lee said.
